HUP0003563A2 - Aminoterminálisa felől csonkolt MCP-2 mint kemokinantagonista - Google Patents
Aminoterminálisa felől csonkolt MCP-2 mint kemokinantagonistaInfo
- Publication number
- HUP0003563A2 HUP0003563A2 HU0003563A HUP0003563A HUP0003563A2 HU P0003563 A2 HUP0003563 A2 HU P0003563A2 HU 0003563 A HU0003563 A HU 0003563A HU P0003563 A HUP0003563 A HU P0003563A HU P0003563 A2 HUP0003563 A2 HU P0003563A2
- Authority
- HU
- Hungary
- Prior art keywords
- mcp
- amino
- truncated
- diseases
- terminally truncated
- Prior art date
Links
- 102000019034 Chemokines Human genes 0.000 title 1
- 108010012236 Chemokines Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 102100034871 C-C motif chemokine 8 Human genes 0.000 abstract 4
- 101710155833 C-C motif chemokine 8 Proteins 0.000 abstract 4
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 abstract 4
- 150000001413 amino acids Chemical group 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 239000002559 chemokine receptor antagonist Substances 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 230000011132 hemopoiesis Effects 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 210000005166 vasculature Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A találmány tárgya aminoterminálisa felől csonkolt MCP-2, amelykemokinantagonista aktivitású, és amelyből hiányoznak a természetesenelőforduló MCP-2 1., 1-2., 1-3., 1-4. vagy 1-5. aminosavainakmegfelelő aminoterminális aminosavak. A találmány tárgyát képeziktovábbá a csonkolt MCP-2-t kódoló DNS-molekulák, az ezeket tartalmazóexpressziós vektorok és gazdasejtek, továbbá csonkolt MCP-2alkalmazásai és eljárások előállítására. A találmány szerinti megoldásalkalmazható kemokinhatások antagonista aktivitását igénylőbetegségek, közelebbről gyulladásos betegségek, HIV-fertőzés, ér- ésvérképződéssel kapcsolatos betegségek és tumorok terápiájában és/vagydiagnózisában. Ó
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97116863A EP0906954A1 (en) | 1997-09-29 | 1997-09-29 | Amino-terminal truncated c-c chemokines as chemokine antagonist |
| EP97122471A EP0905240A1 (en) | 1997-09-29 | 1997-12-19 | Amino-terminally truncated c-c chemokines as chemokine antagonists |
| EP98104216A EP0905241A1 (en) | 1997-09-29 | 1998-03-10 | Amino-terminally truncated c-c chemokines as chemokine antagonists |
| PCT/EP1998/006142 WO1999016876A1 (en) | 1997-09-29 | 1998-09-28 | Amino-terminally truncated mcp-2 as chemokine antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HUP0003563A2 true HUP0003563A2 (hu) | 2001-02-28 |
| HUP0003563A3 HUP0003563A3 (en) | 2005-11-28 |
| HU226468B1 HU226468B1 (en) | 2008-12-29 |
Family
ID=8227408
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0003505A HU226414B1 (en) | 1997-09-29 | 1998-09-28 | Amino-terminally truncated rantes as chemokine antagonists |
| HU0003563A HU226468B1 (en) | 1997-09-29 | 1998-09-28 | Amino-terminally truncated mcp-2-as chemokine antagonists |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0003505A HU226414B1 (en) | 1997-09-29 | 1998-09-28 | Amino-terminally truncated rantes as chemokine antagonists |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US6977071B2 (hu) |
| EP (6) | EP0906954A1 (hu) |
| JP (2) | JP4233214B2 (hu) |
| KR (2) | KR100542934B1 (hu) |
| CN (3) | CN1233415C (hu) |
| AR (2) | AR013528A1 (hu) |
| AT (3) | ATE263242T1 (hu) |
| AU (2) | AU750341B2 (hu) |
| BG (2) | BG64679B1 (hu) |
| BR (2) | BR9812565A (hu) |
| CA (2) | CA2305017A1 (hu) |
| CY (1) | CY1110927T1 (hu) |
| CZ (2) | CZ299479B6 (hu) |
| DE (3) | DE69822856T2 (hu) |
| DK (3) | DK1021541T3 (hu) |
| EA (2) | EA003942B1 (hu) |
| EE (2) | EE200000152A (hu) |
| ES (3) | ES2287601T3 (hu) |
| HK (3) | HK1062637A1 (hu) |
| HU (2) | HU226414B1 (hu) |
| IL (2) | IL135351A (hu) |
| NO (2) | NO20001584D0 (hu) |
| NZ (3) | NZ516027A (hu) |
| PL (2) | PL196427B1 (hu) |
| PT (3) | PT1439231E (hu) |
| SK (2) | SK286439B6 (hu) |
| UA (2) | UA73081C2 (hu) |
| WO (2) | WO1999016877A1 (hu) |
| ZA (2) | ZA988676B (hu) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7067117B1 (en) | 1997-09-11 | 2006-06-27 | Cambridge University Technical Services, Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
| US6989435B2 (en) | 1997-09-11 | 2006-01-24 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
| US6534626B1 (en) * | 1997-12-01 | 2003-03-18 | The United States Of America As Represented By The Department Of Health & Human Services | Chemokine variants |
| US7238711B1 (en) | 1999-03-17 | 2007-07-03 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
| DE60030749T2 (de) * | 1999-10-25 | 2007-09-20 | Pharis Biotec Gmbh | Prozessiertes menschliches chemokin phc-1 |
| EP1167527A1 (en) * | 2000-06-22 | 2002-01-02 | Euroscreen S.A. | Processed human chemokines PHC-1 and PHC-2 |
| AU2505601A (en) * | 1999-11-15 | 2001-05-30 | Wolf-Georg Forssmann | Novel use of hcc-2 |
| CA2316405A1 (en) * | 2000-05-26 | 2001-11-26 | Ian Clark-Lewis | Modulation of inflammation by protease products |
| EP1176200A3 (de) | 2000-06-20 | 2005-01-12 | Switch Biotech Aktiengesellschaft | Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen |
| UA77950C2 (en) * | 2000-10-04 | 2007-02-15 | Applied Research Systems | Use of mutants of cc chemokines for treatment of multiple sclerosis |
| GB2373785A (en) * | 2001-03-28 | 2002-10-02 | Rega Inst For Medical Res | Truncating chemokines using dipeptidyl peptidase IV |
| US7553483B2 (en) | 2001-12-17 | 2009-06-30 | Merck Serono Sa | Chemokine mutants acting as chemokine antagonists |
| WO2004104216A2 (en) * | 2003-05-21 | 2004-12-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4) |
| DE102005049637A1 (de) * | 2005-10-14 | 2007-04-26 | Rheinisch-Westfälische Technische Hochschule Aachen | Antagonisten gegen die Interaktion von PF4 und RANTES |
| DK2185719T3 (en) | 2007-08-02 | 2014-02-17 | Novimmune Sa | ANTI-RANTES ANTIBODIES AND PROCEDURES FOR USE THEREOF |
| WO2011097567A1 (en) * | 2010-02-08 | 2011-08-11 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Rantes multiplexed assay, rantes variants related to disease, and rantes variants related to enzymatice activity |
| US9296803B2 (en) | 2010-03-11 | 2016-03-29 | Health Research, Inc. | Methods and compositions containing Fc fusion proteins for enhancing immune responses |
| TW201718851A (zh) * | 2015-09-18 | 2017-06-01 | 通用醫院公司 | 具有抗化學排斥(anti-fugetactic)性質之經修飾自然殺手細胞及其用途 |
| EP3813869B1 (en) | 2018-05-28 | 2023-10-18 | Université de Genève | Ccr5 inhibitor for use in treating a neuroinflammatory disorder that involves cerebral inflammation |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
| US11402391B2 (en) | 2020-12-21 | 2022-08-02 | Incelldx, Inc. | Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01265099A (ja) | 1987-10-08 | 1989-10-23 | Stichting Rega Vzw | 抗ｈｉｖ活性をもつ３’，−フルオロプリン−２’，３’−ジデオキシリボシド類 |
| US5739103A (en) * | 1993-11-12 | 1998-04-14 | Dana-Farber Cancer Institute | Chemokine N-terminal deletion mutations |
| WO1996017935A2 (en) * | 1994-12-08 | 1996-06-13 | Glaxo Group Limited | Rantes peptide and fragments and compositions comprising it for treatment of inflammation |
| WO1997025427A1 (en) * | 1996-01-12 | 1997-07-17 | Genetics Institute, Inc. | Beta-chemokine, h1305 (mcp-2) |
| WO1997035982A2 (en) * | 1996-03-27 | 1997-10-02 | Icos Corporation | Monocyte chemotactic protein-5 materials and methods |
| FR2748938B1 (fr) * | 1996-05-22 | 1998-07-31 | Pasteur Institut | Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih |
| US6168784B1 (en) * | 1997-09-03 | 2001-01-02 | Gryphon Sciences | N-terminal modifications of RANTES and methods of use |
-
1997
- 1997-09-29 EP EP97116863A patent/EP0906954A1/en not_active Withdrawn
- 1997-12-19 EP EP97122471A patent/EP0905240A1/en not_active Withdrawn
-
1998
- 1998-03-10 EP EP98104216A patent/EP0905241A1/en not_active Withdrawn
- 1998-09-22 ZA ZA9808676A patent/ZA988676B/xx unknown
- 1998-09-22 ZA ZA9808675A patent/ZA988675B/xx unknown
- 1998-09-28 AU AU97474/98A patent/AU750341B2/en not_active Ceased
- 1998-09-28 HU HU0003505A patent/HU226414B1/hu not_active IP Right Cessation
- 1998-09-28 CZ CZ20001147A patent/CZ299479B6/cs not_active IP Right Cessation
- 1998-09-28 ES ES04007579T patent/ES2287601T3/es not_active Expired - Lifetime
- 1998-09-28 PL PL339545A patent/PL196427B1/pl not_active IP Right Cessation
- 1998-09-28 DE DE69822856T patent/DE69822856T2/de not_active Expired - Lifetime
- 1998-09-28 EP EP04007579A patent/EP1439231B1/en not_active Expired - Lifetime
- 1998-09-28 CZ CZ20001146A patent/CZ299478B6/cs not_active IP Right Cessation
- 1998-09-28 AT AT98951476T patent/ATE263242T1/de active
- 1998-09-28 EA EA200000378A patent/EA003942B1/ru not_active IP Right Cessation
- 1998-09-28 PT PT04007579T patent/PT1439231E/pt unknown
- 1998-09-28 EP EP98951476A patent/EP1019507B1/en not_active Expired - Lifetime
- 1998-09-28 JP JP2000513947A patent/JP4233214B2/ja not_active Expired - Fee Related
- 1998-09-28 EE EEP200000152A patent/EE200000152A/xx unknown
- 1998-09-28 AR ARP980104819A patent/AR013528A1/es active IP Right Grant
- 1998-09-28 KR KR1020007003020A patent/KR100542934B1/ko not_active IP Right Cessation
- 1998-09-28 DK DK98947553T patent/DK1021541T3/da active
- 1998-09-28 CA CA002305017A patent/CA2305017A1/en not_active Abandoned
- 1998-09-28 HU HU0003563A patent/HU226468B1/hu not_active IP Right Cessation
- 1998-09-28 NZ NZ516027A patent/NZ516027A/en unknown
- 1998-09-28 NZ NZ503235A patent/NZ503235A/xx unknown
- 1998-09-28 CA CA002304827A patent/CA2304827A1/en not_active Abandoned
- 1998-09-28 CN CNB031492991A patent/CN1233415C/zh not_active Expired - Fee Related
- 1998-09-28 AR ARP980104820A patent/AR013529A1/es active IP Right Grant
- 1998-09-28 PT PT98951476T patent/PT1019507E/pt unknown
- 1998-09-28 DE DE69823218T patent/DE69823218T2/de not_active Expired - Lifetime
- 1998-09-28 UA UA2000042499A patent/UA73081C2/uk unknown
- 1998-09-28 EA EA200000379A patent/EA003940B1/ru not_active IP Right Cessation
- 1998-09-28 DE DE69838188T patent/DE69838188T2/de not_active Expired - Lifetime
- 1998-09-28 SK SK450-2000A patent/SK286439B6/sk not_active IP Right Cessation
- 1998-09-28 DK DK98951476T patent/DK1019507T3/da active
- 1998-09-28 ES ES98951476T patent/ES2218860T3/es not_active Expired - Lifetime
- 1998-09-28 CN CNB988095696A patent/CN1145693C/zh not_active Expired - Fee Related
- 1998-09-28 KR KR1020007003019A patent/KR100560275B1/ko not_active IP Right Cessation
- 1998-09-28 EE EEP200000151A patent/EE200000151A/xx unknown
- 1998-09-28 CN CNB988095726A patent/CN1148447C/zh not_active Expired - Fee Related
- 1998-09-28 PT PT98947553T patent/PT1021541E/pt unknown
- 1998-09-28 BR BR9812565-6A patent/BR9812565A/pt not_active Application Discontinuation
- 1998-09-28 UA UA2000042496A patent/UA73080C2/uk unknown
- 1998-09-28 AT AT98947553T patent/ATE264390T1/de active
- 1998-09-28 WO PCT/EP1998/006143 patent/WO1999016877A1/en active IP Right Grant
- 1998-09-28 WO PCT/EP1998/006142 patent/WO1999016876A1/en active IP Right Grant
- 1998-09-28 NZ NZ503234A patent/NZ503234A/en unknown
- 1998-09-28 AU AU94420/98A patent/AU750606B2/en not_active Ceased
- 1998-09-28 DK DK04007579T patent/DK1439231T3/da active
- 1998-09-28 SK SK451-2000A patent/SK286495B6/sk not_active IP Right Cessation
- 1998-09-28 PL PL339559A patent/PL197569B1/pl not_active IP Right Cessation
- 1998-09-28 JP JP2000513946A patent/JP4230659B2/ja not_active Expired - Fee Related
- 1998-09-28 EP EP98947553A patent/EP1021541B1/en not_active Expired - Lifetime
- 1998-09-28 ES ES98947553T patent/ES2215324T3/es not_active Expired - Lifetime
- 1998-09-28 BR BR9812394-7A patent/BR9812394A/pt not_active Application Discontinuation
- 1998-09-28 AT AT04007579T patent/ATE368742T1/de active
-
2000
- 2000-03-22 BG BG104266A patent/BG64679B1/bg unknown
- 2000-03-22 BG BG104267A patent/BG64757B1/bg unknown
- 2000-03-27 NO NO20001584A patent/NO20001584D0/no not_active Application Discontinuation
- 2000-03-28 NO NO20001609A patent/NO20001609L/no unknown
- 2000-03-28 US US09/537,858 patent/US6977071B2/en not_active Expired - Fee Related
- 2000-03-28 US US09/537,859 patent/US6905676B2/en not_active Expired - Fee Related
- 2000-03-29 IL IL135351A patent/IL135351A/en not_active IP Right Cessation
- 2000-03-29 IL IL135352A patent/IL135352A/en not_active IP Right Cessation
-
2001
- 2001-04-25 HK HK04105182A patent/HK1062637A1/xx not_active IP Right Cessation
- 2001-04-25 HK HK01102961A patent/HK1032425A1/xx not_active IP Right Cessation
- 2001-04-25 HK HK01102962A patent/HK1032426A1/xx not_active IP Right Cessation
-
2005
- 2005-03-07 US US11/072,454 patent/US7326411B2/en not_active Expired - Fee Related
- 2005-05-06 US US11/123,089 patent/US7338653B2/en not_active Expired - Fee Related
- 2005-05-18 US US11/131,221 patent/US20050220790A1/en not_active Abandoned
-
2007
- 2007-10-08 CY CY20071101290T patent/CY1110927T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0003563A2 (hu) | Aminoterminálisa felől csonkolt MCP-2 mint kemokinantagonista | |
| DK0559884T3 (da) | Rekombinante virusvektorer til ekspression i muskelceller | |
| ATE77104T1 (de) | Menge und verfahren zur herstellung rekombinierter erzeugnisse in grosser ausbeute. | |
| ATE182901T1 (de) | Für androgen-rezeptor-protein kodierende dna | |
| ATE256181T1 (de) | Menschlicher c3b/c4b-rezeptor (cr1) | |
| DE69738581D1 (de) | Menschliche dnase i hyperaktive varianten | |
| MX9805300A (es) | Acidos nucleicos que codifican factor-2 inductor de interferon gama. | |
| NO985742D0 (no) | IL-1/TNF-<alfa>-aktivert kinase (ITAK) og fremgangsmÕter for fremstilling og anvendelse av denne | |
| CA2250433A1 (en) | Human dnase ii | |
| BG101846A (en) | HUMAN DNase I VARIANTS | |
| YU48126B (sh) | Postupak za pripremanje proteina plasmodium falciparum-a | |
| DE69739525D1 (de) | Neuer cxc chemokinrezeptor aus maus | |
| DE69636737D1 (de) | Neues immunoregulatorisches protein lst-1 | |
| WO2001092301A3 (en) | Placc, a novel human c-c chemokine isolated from placenta | |
| BG101847A (en) | Human dnase i variants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of definitive patent protection due to non-payment of fees |